<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">nogr</journal-id><journal-title-group><journal-title xml:lang="ru">Экспериментальная и клиническая гастроэнтерология</journal-title><trans-title-group xml:lang="en"><trans-title>Experimental and Clinical Gastroenterology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1682-8658</issn><publisher><publisher-name>«Global Media Technologies»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.31146/1682-8658-ecg-224-4-10-19</article-id><article-id custom-type="elpub" pub-id-type="custom">nogr-2753</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ПЕРЕДОВАЯ СТАТЬЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>LEADING ARTICLE</subject></subj-group></article-categories><title-group><article-title>Хронический атрофический гастрит: современное состояние проблемы</article-title><trans-title-group xml:lang="en"><trans-title>Chronic atrophic gastritis: current state of the problem</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4007-7112</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Андреев</surname><given-names>Д. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Andreev</surname><given-names>D. N.</given-names></name></name-alternatives><email xlink:type="simple">dna-mit8@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7760-2091</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кучерявый</surname><given-names>Ю. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kucheryavyi</surname><given-names>Yu. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Российский университет медицины» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Russian University of Medicine</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБОУ ВО «Российский университет медицины» Минздрава России; АО «Ильинская больница»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Russian University of Medicine; JSC “Ilyinskaya Hospital”</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>15</day><month>09</month><year>2024</year></pub-date><volume>0</volume><issue>4</issue><fpage>10</fpage><lpage>19</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Андреев Д.Н., Кучерявый Ю.А., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Андреев Д.Н., Кучерявый Ю.А.</copyright-holder><copyright-holder xml:lang="en">Andreev D.N., Kucheryavyi Y.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.nogr.org/jour/article/view/2753">https://www.nogr.org/jour/article/view/2753</self-uri><abstract><p>Согласно общепринятой концепции, персистирующий диффузный воспалительный процесс в собственной пластинке слизистой оболочки желудка, протекающий в рамках поверхностного неатрофического хронического гастрита, у ряда пациентов имеет потенциал к трансформации в хронический атрофический гастрит (ХАГ), который является первым этапом многоступенчатой модели канцерогенеза желудка (каскад Correa). ХАГ характеризуется истончением слизистой оболочки, потерей специализированных клеток желудочных желез и патологическими изменениями эпителиальных клеток (метаплазия). Принято выделять два основных подтипа ХАГ: экзогенный (EMAG в иностранной литературе) и аутоиммунный (AMAG в иностранной литературе). Этиологическим базисом экзогенного ХАГ преимущественно является инфекция H. pylori, а в основе аутоиммунного ХАГ лежит иммунная агрессия к париетальным клеткам эпителия желудка. Верификация ХАГ возможна только путем патоморфологического исследования. Атрофия и кишечная метаплазия могут быть обратимы при устранении этиологического фактора и длительном лечении пациента, детальная стратегия которого пока не разработана. Однако, применение цикличной или постоянной терапии цитопротекторами представляется наиболее перспективной стратегией на сегодня.</p></abstract><trans-abstract xml:lang="en"><p>According to the generally accepted concept, a persistent diffuse inflammatory process in the lamina propria of the gastric mucosa, occurring within the framework of superficial non-atrophic chronic gastritis, in a number of patients has the potential to transform into chronic atrophic gastritis (CAG), which is the first stage of a multi-stage model of gastric carcinogenesis (Correa cascade). CAH is characterized by thinning of the mucosa, loss of specialized gastric gland cells, and pathological changes in epithelial cells (metaplasia). It is customary to distinguish two main subtypes of CAH: exogenous (EMAG in foreign literature) and autoimmune (AMAG in foreign literature). The etiological basis of exogenous CAH is predominantly H. pylori infection, and autoimmune CAH is based on immune aggression to the parietal cells of the gastric epithelium. Verification of CAH is possible only through pathomorphological examination. Atrophy and intestinal metaplasia can be reversible by eliminating the etiological factor and long-term treatment of the patient, a detailed strategy for which has not yet been developed. However, the use of cyclic or continuous therapy with cytoprotectors seems to be the most promising strategy today.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>хронический атрофический гастрит</kwd><kwd>аутоимунный гастрит</kwd><kwd>Helicobacter pylori</kwd><kwd>метаплазия</kwd><kwd>цитопротекторы</kwd></kwd-group><kwd-group xml:lang="en"><kwd>chronic atrophic gastritis</kwd><kwd>autoimmune gastritis</kwd><kwd>Helicobacter pylori</kwd><kwd>metaplasia</kwd><kwd>cytoprotectors</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Maev I.V., Andreev D. N., Kucheryavyi Yu.A. [Chronic gastritis from the perspective of modern medicine]. Moscow. Prima Print. 2022. (in Russ.)@@ Маев И. В., Андреев Д. Н., Кучерявый Ю. А. Хронический гастрит с позиций современной медицины. М.: Прима Принт; 2022.</mixed-citation><mixed-citation xml:lang="en">Maev I.V., Andreev D. N., Kucheryavyi Yu.A. [Chronic gastritis from the perspective of modern medicine]. Moscow. Prima Print. 2022. (in Russ.)@@ Маев И. В., Андреев Д. Н., Кучерявый Ю. А. Хронический гастрит с позиций современной медицины. М.: Прима Принт; 2022.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Feldman M., Jensen P. J., Howden C. W. Gastritis and Gastropathy. In.: Sleisenger and Fordtran’s Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management / edited by Mark Feldman, Lawrence S. Friedman, Laurence J. Brandt. - 10th ed. 2020.</mixed-citation><mixed-citation xml:lang="en">Feldman M., Jensen P. J., Howden C. W. Gastritis and Gastropathy. In.: Sleisenger and Fordtran’s Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management / edited by Mark Feldman, Lawrence S. Friedman, Laurence J. Brandt. - 10th ed. 2020.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Ivashkin V. T., Maev I. V., Lapina T. L. et al. Clinical Recommendations of Russian Gastroenterological Association and RENDO Endoscopic Society on Diagnosis and Treatment of Gastritis and Duodenitis.Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021;31(4):70-99. (In Russ.) doi: 10.22416/1382-4376-2021-31-4-70-99.@@ Ивашкин В. Т., Маев И. В., Лапина Т. Л. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и ассоциации «Эндоскопическое общество РЭНДО» по диагностике и лечению гастрита, дуоденита. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2021;31(4):70-99. doi: 10.22416/1382-4376-2021-31-4-70-99.</mixed-citation><mixed-citation xml:lang="en">Ivashkin V. T., Maev I. V., Lapina T. L. et al. Clinical Recommendations of Russian Gastroenterological Association and RENDO Endoscopic Society on Diagnosis and Treatment of Gastritis and Duodenitis.Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021;31(4):70-99. (In Russ.) doi: 10.22416/1382-4376-2021-31-4-70-99.@@ Ивашкин В. Т., Маев И. В., Лапина Т. Л. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и ассоциации «Эндоскопическое общество РЭНДО» по диагностике и лечению гастрита, дуоденита. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2021;31(4):70-99. doi: 10.22416/1382-4376-2021-31-4-70-99.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Malfertheiner P., Megraud F., Rokkas T. et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022 Aug 8: gutjnl-2022-327745. doi: 10.1136/gutjnl-2022-327745.</mixed-citation><mixed-citation xml:lang="en">Malfertheiner P., Megraud F., Rokkas T. et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022 Aug 8: gutjnl-2022-327745. doi: 10.1136/gutjnl-2022-327745.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Ivashkin V. T., Mayev I. V., Kaprin A. D. et al. Early Detection of Oncological Diseases of the Digestive System (Guidelines of the Russian Gastroenterological Association and the Russian Association of Oncologists for Primary Care Physicians).Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2019;29(5):53-74. (In Russ.) doi: 10.22416/1382-4376-2019-29-5-53-74.@@ Ивашкин В. Т., Маев И. В., Каприн А. Д. и др. Раннее выявление онкологических заболеваний органов пищеварения (методическое руководство Российской гастроэнтерологической ассоциации и Ассоциации онкологов России для врачей первичного звена здравоохранения). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2019;29(5):53-74. doi: 10.22416/1382-4376-2019-29-5-53-74.</mixed-citation><mixed-citation xml:lang="en">Ivashkin V. T., Mayev I. V., Kaprin A. D. et al. Early Detection of Oncological Diseases of the Digestive System (Guidelines of the Russian Gastroenterological Association and the Russian Association of Oncologists for Primary Care Physicians).Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2019;29(5):53-74. (In Russ.) doi: 10.22416/1382-4376-2019-29-5-53-74.@@ Ивашкин В. Т., Маев И. В., Каприн А. Д. и др. Раннее выявление онкологических заболеваний органов пищеварения (методическое руководство Российской гастроэнтерологической ассоциации и Ассоциации онкологов России для врачей первичного звена здравоохранения). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2019;29(5):53-74. doi: 10.22416/1382-4376-2019-29-5-53-74.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Khatkov I. E., Abdulkhakov S. R., Alekseenko S. A. et al.Russian consensus on prevention, diagnosis and treatment of gastric cancer. Malignant tumours. 2023;13(2):56-68. (In Russ.) doi: 10.18027/2224-5057-2023-13-2-4.@@ Хатьков И. Е., Абдулхаков С. Р., Алексеенко С. А. и др. Российский консенсус по профилактике, диагностике и лечению рака желудка. Злокачественные опухоли. 2023;13(2):56-68. doi: 10.18027/2224-5057-2023-13-2-4.</mixed-citation><mixed-citation xml:lang="en">Khatkov I. E., Abdulkhakov S. R., Alekseenko S. A. et al.Russian consensus on prevention, diagnosis and treatment of gastric cancer. Malignant tumours. 2023;13(2):56-68. (In Russ.) doi: 10.18027/2224-5057-2023-13-2-4.@@ Хатьков И. Е., Абдулхаков С. Р., Алексеенко С. А. и др. Российский консенсус по профилактике, диагностике и лечению рака желудка. Злокачественные опухоли. 2023;13(2):56-68. doi: 10.18027/2224-5057-2023-13-2-4.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">GBD 2017 Stomach Cancer Collaborators. The global, regional, and national burden of stomach cancer in 195 countries, 1990-2017: a systematic analysis for the Global Burden of Disease study 2017. Lancet Gastroenterol Hepatol. 2020 Jan;5(1):42-54. doi: 10.1016/S2468-1253(19)30328-0.</mixed-citation><mixed-citation xml:lang="en">GBD 2017 Stomach Cancer Collaborators. The global, regional, and national burden of stomach cancer in 195 countries, 1990-2017: a systematic analysis for the Global Burden of Disease study 2017. Lancet Gastroenterol Hepatol. 2020 Jan;5(1):42-54. doi: 10.1016/S2468-1253(19)30328-0.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Kaprin A.D., Starinsky V. V., Shakhzadova A. O. [The state of cancer care for the population of Russia in 2021]. Moscow. MNIOI im. P. A. Herzen - branch of the Federal State Budgetary Institution «National Medical Research Center of Radiology» of the Ministry of Health of Russia, 2022. ill. 239 p. ISBN 978-5-85502-275-9. (in Russ.)@@ Состояние онкологической помощи населению России в 2021 году. Под ред. А. Д. Каприна, В. В. Старинского, А. О. Шахзадовой - М.: МНИОИ им. П. А. Герцена - филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2022. - илл. - 239 с. ISBN 978-5-85502-275-9.</mixed-citation><mixed-citation xml:lang="en">Kaprin A.D., Starinsky V. V., Shakhzadova A. O. [The state of cancer care for the population of Russia in 2021]. Moscow. MNIOI im. P. A. Herzen - branch of the Federal State Budgetary Institution «National Medical Research Center of Radiology» of the Ministry of Health of Russia, 2022. ill. 239 p. ISBN 978-5-85502-275-9. (in Russ.)@@ Состояние онкологической помощи населению России в 2021 году. Под ред. А. Д. Каприна, В. В. Старинского, А. О. Шахзадовой - М.: МНИОИ им. П. А. Герцена - филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2022. - илл. - 239 с. ISBN 978-5-85502-275-9.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Huang R.J., Epplein M., Hamashima C. et al. An Approach to the Primary and Secondary Prevention of Gastric Cancer in the United States. Clin Gastroenterol Hepatol. 2022 Oct;20(10):2218-2228.e2. doi: 10.1016/j.cgh.2021.09.039.</mixed-citation><mixed-citation xml:lang="en">Huang R.J., Epplein M., Hamashima C. et al. An Approach to the Primary and Secondary Prevention of Gastric Cancer in the United States. Clin Gastroenterol Hepatol. 2022 Oct;20(10):2218-2228.e2. doi: 10.1016/j.cgh.2021.09.039.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Shah S.C., Piazuelo M. B., Kuipers E. J., Li D. AGA Clinical Practice Update on the Diagnosis and Management of Atrophic Gastritis: Expert Review. Gastroenterology. 2021 Oct;161(4):1325-1332.e7. doi: 10.1053/j.gastro.2021.06.078.</mixed-citation><mixed-citation xml:lang="en">Shah S.C., Piazuelo M. B., Kuipers E. J., Li D. AGA Clinical Practice Update on the Diagnosis and Management of Atrophic Gastritis: Expert Review. Gastroenterology. 2021 Oct;161(4):1325-1332.e7. doi: 10.1053/j.gastro.2021.06.078.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Song H., Ekheden I. G., Zheng Z., Ericsson J., Nyrén O., Ye W. Incidence of gastric cancer among patients with gastric precancerous lesions: observational cohort study in a low risk Western population. BMJ. 2015 Jul 27;351: h3867. doi: 10.1136/bmj.h3867.</mixed-citation><mixed-citation xml:lang="en">Song H., Ekheden I. G., Zheng Z., Ericsson J., Nyrén O., Ye W. Incidence of gastric cancer among patients with gastric precancerous lesions: observational cohort study in a low risk Western population. BMJ. 2015 Jul 27;351: h3867. doi: 10.1136/bmj.h3867.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Rugge M., Savarino E., Sbaraglia M., Bricca L., Malfertheiner P. Gastritis: The clinico-pathological spectrum. Dig Liver Dis. 2021 Oct;53(10):1237-1246. doi: 10.1016/j.dld.2021.03.007.</mixed-citation><mixed-citation xml:lang="en">Rugge M., Savarino E., Sbaraglia M., Bricca L., Malfertheiner P. Gastritis: The clinico-pathological spectrum. Dig Liver Dis. 2021 Oct;53(10):1237-1246. doi: 10.1016/j.dld.2021.03.007.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Maev I. V., Andreev D. N., Samsonov A. A., Fomenko A. K. H. pylori-associated chronic gastritis: status update on the problem. Meditsinskiy sovet = Medical Council. 2022;(15):35-45. (In Russ.) doi: 10.21518/2079-701X-2022-16-15-35-45.@@ Маев И. В., Андреев Д. Н., Самсонов А. А., Фоменко А. К. Helicobacter pylori-ассоциированный хронический гастрит: современное состояние проблемы. Медицинский Совет. 2022;(15):35-45. doi: 10.21518/2079-701X-2022-16-15-35-45.</mixed-citation><mixed-citation xml:lang="en">Maev I. V., Andreev D. N., Samsonov A. A., Fomenko A. K. H. pylori-associated chronic gastritis: status update on the problem. Meditsinskiy sovet = Medical Council. 2022;(15):35-45. (In Russ.) doi: 10.21518/2079-701X-2022-16-15-35-45.@@ Маев И. В., Андреев Д. Н., Самсонов А. А., Фоменко А. К. Helicobacter pylori-ассоциированный хронический гастрит: современное состояние проблемы. Медицинский Совет. 2022;(15):35-45. doi: 10.21518/2079-701X-2022-16-15-35-45.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Hooi J.K.Y., Lai W. Y., Ng W. K. et al. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology. 2017 Aug;153(2):420-429. doi: 10.1053/j.gastro.2017.04.022.</mixed-citation><mixed-citation xml:lang="en">Hooi J.K.Y., Lai W. Y., Ng W. K. et al. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology. 2017 Aug;153(2):420-429. doi: 10.1053/j.gastro.2017.04.022.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Zamani M., Ebrahimtabar F., Zamani V. et al. Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection. Aliment Pharmacol Ther. 2018 Apr;47(7):868-876. doi: 10.1111/apt.14561.</mixed-citation><mixed-citation xml:lang="en">Zamani M., Ebrahimtabar F., Zamani V. et al. Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection. Aliment Pharmacol Ther. 2018 Apr;47(7):868-876. doi: 10.1111/apt.14561.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Li Y., Choi H., Leung K., Jiang F., Graham D. Y., Leung W. K. Global prevalence of Helicobacter pylori infection between 1980 and 2022: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023 Jun;8(6):553-564. doi: 10.1016/S2468-1253(23)00070-5.</mixed-citation><mixed-citation xml:lang="en">Li Y., Choi H., Leung K., Jiang F., Graham D. Y., Leung W. K. Global prevalence of Helicobacter pylori infection between 1980 and 2022: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023 Jun;8(6):553-564. doi: 10.1016/S2468-1253(23)00070-5.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang Y., Weck M. N., Schöttker B., Rothenbacher D., Brenner H. Gastric parietal cell antibodies, Helicobacter pylori infection, and chronic atrophic gastritis: evidence from a large population-based study in Germany. Cancer Epidemiol Biomarkers Prev. 2013 May;22(5):821-6. doi: 10.1158/1055-9965.EPI-12-1343.</mixed-citation><mixed-citation xml:lang="en">Zhang Y., Weck M. N., Schöttker B., Rothenbacher D., Brenner H. Gastric parietal cell antibodies, Helicobacter pylori infection, and chronic atrophic gastritis: evidence from a large population-based study in Germany. Cancer Epidemiol Biomarkers Prev. 2013 May;22(5):821-6. doi: 10.1158/1055-9965.EPI-12-1343.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Wang S.M., Roth M. J., Murphy G. A., Dawsey S. M., Fan J. H., Taylor P. R., Qiao Y. L., Abnet C. C. Serologic Profile of Antiparietal Cell Antibodies, Pepsinogens, and H. pylori and Risk of Upper Gastrointestinal Cancer: A Nested Case-Control Study in China. Cancer Epidemiol Biomarkers Prev. 2019 Dec;28(12):2022-2029. doi: 10.1158/1055-9965.</mixed-citation><mixed-citation xml:lang="en">Wang S.M., Roth M. J., Murphy G. A., Dawsey S. M., Fan J. H., Taylor P. R., Qiao Y. L., Abnet C. C. Serologic Profile of Antiparietal Cell Antibodies, Pepsinogens, and H. pylori and Risk of Upper Gastrointestinal Cancer: A Nested Case-Control Study in China. Cancer Epidemiol Biomarkers Prev. 2019 Dec;28(12):2022-2029. doi: 10.1158/1055-9965.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Orgler E., Dabsch S., Malfertheiner P. et al. Autoimmune Gastritis: Update and New Perspectives in Therapeutic Management. Curr Treat Options Gastro. 2023; 21, 64-77. doi:10.1007/s11938-023-00406-4.</mixed-citation><mixed-citation xml:lang="en">Orgler E., Dabsch S., Malfertheiner P. et al. Autoimmune Gastritis: Update and New Perspectives in Therapeutic Management. Curr Treat Options Gastro. 2023; 21, 64-77. doi:10.1007/s11938-023-00406-4.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Ministry of Health of the Russian Federation Department of Monitoring, Analysis and Strategic Development of Health Care FSBI [Central Research Institute of Organization and Informatization of Health Care” of the Ministry of Health of Russia. Morbidity rate of the entire population of Russia in 2019: statistical materials]. Moscow, 2020. (in Russ.)@@ Министерство здравоохранения Российской Федерации Департамент мониторинга, анализа и стратегического развития здравоохранения ФГБУ «Центральный научно-исследовательский институт организации и информатизации здравоохранения» Минздрава России. Заболеваемость всего населения России в 2019 году: статистические материалы. Москва, 2020.</mixed-citation><mixed-citation xml:lang="en">Ministry of Health of the Russian Federation Department of Monitoring, Analysis and Strategic Development of Health Care FSBI [Central Research Institute of Organization and Informatization of Health Care” of the Ministry of Health of Russia. Morbidity rate of the entire population of Russia in 2019: statistical materials]. Moscow, 2020. (in Russ.)@@ Министерство здравоохранения Российской Федерации Департамент мониторинга, анализа и стратегического развития здравоохранения ФГБУ «Центральный научно-исследовательский институт организации и информатизации здравоохранения» Минздрава России. Заболеваемость всего населения России в 2019 году: статистические материалы. Москва, 2020.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Yin Y., Liang H., Wei N., Zheng Z. Prevalence of chronic atrophic gastritis worldwide from 2010 to 2020: an updated systematic review and meta-analysis. Ann Palliat Med. 2022 Dec;11(12):3697-3703.</mixed-citation><mixed-citation xml:lang="en">Yin Y., Liang H., Wei N., Zheng Z. Prevalence of chronic atrophic gastritis worldwide from 2010 to 2020: an updated systematic review and meta-analysis. Ann Palliat Med. 2022 Dec;11(12):3697-3703.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Mülder D.T., Hahn A. I., Huang R. J. et al. Prevalence of Gastric Precursor Lesions in Countries with Differential Gastric Cancer Burden: A Systematic Review &amp; Meta-Analysis. Clin Gastroenterol Hepatol. 2024 Mar 2: S1542-3565(24)00227-1. doi: 10.1016/j.cgh.2024.02.023.</mixed-citation><mixed-citation xml:lang="en">Mülder D.T., Hahn A. I., Huang R. J. et al. Prevalence of Gastric Precursor Lesions in Countries with Differential Gastric Cancer Burden: A Systematic Review &amp; Meta-Analysis. Clin Gastroenterol Hepatol. 2024 Mar 2: S1542-3565(24)00227-1. doi: 10.1016/j.cgh.2024.02.023.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Maev I.V., Andreev D. N., Samsonov A. A., Dicheva D. T., Partsvania-Vinogradova E. V. The evolution of ideas about definitions, classification, diagnosis and treatment of gastritis associated with helicobacter pylori infection (on materials of the Kyoto consensus, 2015). Farmateka. 2016;(6):24-33. (in Russ.)@@ Маев И. В., Андреев Д. Н., Самсонов А. А. и др. Эволюция представлений о дефиниции, классификации, диагностике и лечении гастрита, ассоциированного с инфекцией Helicobacter pylori (по материалам Киотского консенсуса, 2015). Фарматека. 2016; (6): 24-33.</mixed-citation><mixed-citation xml:lang="en">Maev I.V., Andreev D. N., Samsonov A. A., Dicheva D. T., Partsvania-Vinogradova E. V. The evolution of ideas about definitions, classification, diagnosis and treatment of gastritis associated with helicobacter pylori infection (on materials of the Kyoto consensus, 2015). Farmateka. 2016;(6):24-33. (in Russ.)@@ Маев И. В., Андреев Д. Н., Самсонов А. А. и др. Эволюция представлений о дефиниции, классификации, диагностике и лечении гастрита, ассоциированного с инфекцией Helicobacter pylori (по материалам Киотского консенсуса, 2015). Фарматека. 2016; (6): 24-33.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Maev I.V., Samsonov A. A., Andreev D. N., Grechushnikov V. B., Korovina T. I. Clinical significance of Helicobacter pylori infection. Clinical medicine. 2013;91(8):4-12. (in Russ.)@@ Маев И. В., Самсонов А. А., Андреев Д. Н., Гречушников В. Б., Коровина Т. И. Клиническое значение инфекции Helicobacter pylori. Клиническая медицина. 2013;91(8):4-12.</mixed-citation><mixed-citation xml:lang="en">Maev I.V., Samsonov A. A., Andreev D. N., Grechushnikov V. B., Korovina T. I. Clinical significance of Helicobacter pylori infection. Clinical medicine. 2013;91(8):4-12. (in Russ.)@@ Маев И. В., Самсонов А. А., Андреев Д. Н., Гречушников В. Б., Коровина Т. И. Клиническое значение инфекции Helicobacter pylori. Клиническая медицина. 2013;91(8):4-12.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Bordin D., Morozov S., Plavnik R., Bakulina N., Voynovan I., Skibo I., Isakov V., Bakulin I., Andreev D., Maev I. Helicobacter pylori infection prevalence in ambulatory settings in 2017-2019 in RUSSIA: The data of real-world national multicenter trial. Helicobacter. 2022 Oct;27(5): e12924. doi: 10.1111/hel.12924.</mixed-citation><mixed-citation xml:lang="en">Bordin D., Morozov S., Plavnik R., Bakulina N., Voynovan I., Skibo I., Isakov V., Bakulin I., Andreev D., Maev I. Helicobacter pylori infection prevalence in ambulatory settings in 2017-2019 in RUSSIA: The data of real-world national multicenter trial. Helicobacter. 2022 Oct;27(5): e12924. doi: 10.1111/hel.12924.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Maev I.V., Samsonov A. A., Andreev D. N. [Helicobacter pylori infection]. Moscow. GEOTAR-Media. 2016. (in Russ.)@@ Маев И. В., Самсонов А. А., Андреев Д. Н. Инфекция Helicobacter pylori. М.: ГЭОТАР-Медиа; 2016.</mixed-citation><mixed-citation xml:lang="en">Maev I.V., Samsonov A. A., Andreev D. N. [Helicobacter pylori infection]. Moscow. GEOTAR-Media. 2016. (in Russ.)@@ Маев И. В., Самсонов А. А., Андреев Д. Н. Инфекция Helicobacter pylori. М.: ГЭОТАР-Медиа; 2016.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Basso D., Plebani M., Kusters J. G. Pathogenesis of Helicobacter pylori infection. Helicobacter. 2010 Sep;15 Suppl 1:14-20. doi: 10.1111/j.1523-5378.2010.00781.x.</mixed-citation><mixed-citation xml:lang="en">Basso D., Plebani M., Kusters J. G. Pathogenesis of Helicobacter pylori infection. Helicobacter. 2010 Sep;15 Suppl 1:14-20. doi: 10.1111/j.1523-5378.2010.00781.x.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Backert S., Clyne M. Pathogenesis of Helicobacter pylori infection. Helicobacter. 2011 Sep;16 Suppl 1:19-25. doi: 10.1111/j.1523-5378.2011.00876.x.</mixed-citation><mixed-citation xml:lang="en">Backert S., Clyne M. Pathogenesis of Helicobacter pylori infection. Helicobacter. 2011 Sep;16 Suppl 1:19-25. doi: 10.1111/j.1523-5378.2011.00876.x.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Varbanova M., Frauenschläger K., Malfertheiner P. Chronic gastritis - an update. Best Pract Res Clin Gastroenterol. 2014 Dec;28(6):1031-42. doi: 10.1016/j.bpg.2014.10.005.</mixed-citation><mixed-citation xml:lang="en">Varbanova M., Frauenschläger K., Malfertheiner P. Chronic gastritis - an update. Best Pract Res Clin Gastroenterol. 2014 Dec;28(6):1031-42. doi: 10.1016/j.bpg.2014.10.005.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Best L.M., Takwoingi Y., Siddique S., Selladurai A., Gandhi A., Low B., Yaghoobi M., Gurusamy K. S. Non-invasive diagnostic tests for Helicobacter pylori infection. Cochrane Database Syst Rev. 2018;3(3): CD012080. doi: 10.1002/14651858.CD012080.pub2.</mixed-citation><mixed-citation xml:lang="en">Best L.M., Takwoingi Y., Siddique S., Selladurai A., Gandhi A., Low B., Yaghoobi M., Gurusamy K. S. Non-invasive diagnostic tests for Helicobacter pylori infection. Cochrane Database Syst Rev. 2018;3(3): CD012080. doi: 10.1002/14651858.CD012080.pub2.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Sugano K., Tack J., Kuipers E. J., Graham D. Y., El-Omar E.M., Miura S., Haruma K., Asaka M., Uemura N., Malfertheiner P.; faculty members of Kyoto Global Consensus Conference. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015 Sep;64(9):1353-67. doi: 10.1136/gutjnl-2015-309252.</mixed-citation><mixed-citation xml:lang="en">Sugano K., Tack J., Kuipers E. J., Graham D. Y., El-Omar E.M., Miura S., Haruma K., Asaka M., Uemura N., Malfertheiner P.; faculty members of Kyoto Global Consensus Conference. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015 Sep;64(9):1353-67. doi: 10.1136/gutjnl-2015-309252.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Ikeda F., Shikata K., Hata J. et al.Combination of Helicobacter pylori Antibody and Serum Pepsinogen as a Good Predictive Tool of Gastric Cancer Incidence: 20-Year Prospective Data From the Hisayama Study. J Epidemiol. 2016 Dec 5;26(12):629-636. doi: 10.2188/jea.JE20150258.</mixed-citation><mixed-citation xml:lang="en">Ikeda F., Shikata K., Hata J. et al.Combination of Helicobacter pylori Antibody and Serum Pepsinogen as a Good Predictive Tool of Gastric Cancer Incidence: 20-Year Prospective Data From the Hisayama Study. J Epidemiol. 2016 Dec 5;26(12):629-636. doi: 10.2188/jea.JE20150258.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Kurilovich S., Belkovets A., Reshetnikov O. et al. Stomach-specific Biomarkers (GastroPanel) Can Predict the Development of Gastric Cancer in a Caucasian Population: A Longitudinal Nested Case-Control Study in Siberia. Anticancer Res. 2016 Jan;36(1):247-53. PMID: 26722050</mixed-citation><mixed-citation xml:lang="en">Kurilovich S., Belkovets A., Reshetnikov O. et al. Stomach-specific Biomarkers (GastroPanel) Can Predict the Development of Gastric Cancer in a Caucasian Population: A Longitudinal Nested Case-Control Study in Siberia. Anticancer Res. 2016 Jan;36(1):247-53. PMID: 26722050</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Shi Y., Wei N., Wang K., Tao T., Yu F., Lv B. Diagnostic value of artificial intelligence-assisted endoscopy for chronic atrophic gastritis: a systematic review and meta-analysis. Front Med (Lausanne). 2023 May 2;10:1134980. doi: 10.3389/fmed.2023.1134980.</mixed-citation><mixed-citation xml:lang="en">Shi Y., Wei N., Wang K., Tao T., Yu F., Lv B. Diagnostic value of artificial intelligence-assisted endoscopy for chronic atrophic gastritis: a systematic review and meta-analysis. Front Med (Lausanne). 2023 May 2;10:1134980. doi: 10.3389/fmed.2023.1134980.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Rugge M., Sugano K., Sacchi D., Sbaraglia M., Malfertheiner P. Gastritis: An Update in 2020. Curr Treatment Options Gastroenterol. 2020;18(3):488-503. doi: 10.1007/s11938-020-00298-8.</mixed-citation><mixed-citation xml:lang="en">Rugge M., Sugano K., Sacchi D., Sbaraglia M., Malfertheiner P. Gastritis: An Update in 2020. Curr Treatment Options Gastroenterol. 2020;18(3):488-503. doi: 10.1007/s11938-020-00298-8.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Maev I.V., Andreev D. N., Zaborovsky A. V., Lobanova E. G. Current status and prospects of using the prokinetic acotiamide in gastroenterology: A review. Terapevticheskii Arkhiv (Ter. Arkh.). (in Russ.) 2023;95(8):716-721. doi: 10.26442/00403660.2023.08.202396.@@ Маев И. В., Андреев Д. Н., Заборовский А. В., Лобанова Е. Г. Реалии и перспективы применения прокинетика акотиамида в гастроэнтерологии. Терапевтический архив. 2023;95(8):716-721. doi: 10.26442/00403660.2023.08.202396.</mixed-citation><mixed-citation xml:lang="en">Maev I.V., Andreev D. N., Zaborovsky A. V., Lobanova E. G. Current status and prospects of using the prokinetic acotiamide in gastroenterology: A review. Terapevticheskii Arkhiv (Ter. Arkh.). (in Russ.) 2023;95(8):716-721. doi: 10.26442/00403660.2023.08.202396.@@ Маев И. В., Андреев Д. Н., Заборовский А. В., Лобанова Е. Г. Реалии и перспективы применения прокинетика акотиамида в гастроэнтерологии. Терапевтический архив. 2023;95(8):716-721. doi: 10.26442/00403660.2023.08.202396.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Sugano K. Effect of Helicobacter pylori eradication on the incidence of gastric cancer: a systematic review and meta-analysis. Gastric Cancer. 2019 May;22(3):435-445. doi: 10.1007/s10120-018-0876-0.</mixed-citation><mixed-citation xml:lang="en">Sugano K. Effect of Helicobacter pylori eradication on the incidence of gastric cancer: a systematic review and meta-analysis. Gastric Cancer. 2019 May;22(3):435-445. doi: 10.1007/s10120-018-0876-0.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Ford A.C., Yuan Y., Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer: systematic review and meta-analysis. Gut. 2020 Dec;69(12):2113-2121. doi: 10.1136/gutjnl-2020-320839.</mixed-citation><mixed-citation xml:lang="en">Ford A.C., Yuan Y., Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer: systematic review and meta-analysis. Gut. 2020 Dec;69(12):2113-2121. doi: 10.1136/gutjnl-2020-320839.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Chen H.N., Wang Z., Li X., Zhou Z. G. Helicobacter pylori eradication cannot reduce the risk of gastric cancer in patients with intestinal metaplasia and dysplasia: evidence from a meta-analysis. Gastric Cancer. 2016 Jan;19(1):166-75. doi: 10.1007/s10120-015-0462-7.</mixed-citation><mixed-citation xml:lang="en">Chen H.N., Wang Z., Li X., Zhou Z. G. Helicobacter pylori eradication cannot reduce the risk of gastric cancer in patients with intestinal metaplasia and dysplasia: evidence from a meta-analysis. Gastric Cancer. 2016 Jan;19(1):166-75. doi: 10.1007/s10120-015-0462-7.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Rokkas T., Rokka A., Portincasa P. A systematic review and meta-analysis of the role of Helicobacter pylori eradication in preventing gastric cancer. Ann Gastroenterol. 2017;30(4):414-423. doi: 10.20524/aog.2017.0144.</mixed-citation><mixed-citation xml:lang="en">Rokkas T., Rokka A., Portincasa P. A systematic review and meta-analysis of the role of Helicobacter pylori eradication in preventing gastric cancer. Ann Gastroenterol. 2017;30(4):414-423. doi: 10.20524/aog.2017.0144.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Pimentel-Nunes P., Libânio D., Marcos-Pinto R. et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy. 2019 Apr;51(4):365-388. doi: 10.1055/a-0859-1883.</mixed-citation><mixed-citation xml:lang="en">Pimentel-Nunes P., Libânio D., Marcos-Pinto R. et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy. 2019 Apr;51(4):365-388. doi: 10.1055/a-0859-1883.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Liang Y., Yang Y., Nong R. et al. Do atrophic gastritis and intestinal metaplasia reverse after Helicobacter pylori eradication? Helicobacter. 2024;29(1): e13042. doi: 10.1111/hel.13042.</mixed-citation><mixed-citation xml:lang="en">Liang Y., Yang Y., Nong R. et al. Do atrophic gastritis and intestinal metaplasia reverse after Helicobacter pylori eradication? Helicobacter. 2024;29(1): e13042. doi: 10.1111/hel.13042.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Andreev D.N., Maev I. V., Kucheryavyy Y. A. Helicobacter pylori resistance in the Russian Federation: a meta-analysis of studies over the past 10 years. Therapeutic Archive. 2020; 92 (11): 24-30. (in Russ.) doi: 10.26442/00403660. 2020.11.000795.@@ Андреев Д. Н., Маев И. В., Кучерявый Ю. А. Резистентность Helicobacter pylori в Российской Федерации: метаанализ исследований за последние 10 лет. Терапевтический архив. 2020;92(11): 24-30.</mixed-citation><mixed-citation xml:lang="en">Andreev D.N., Maev I. V., Kucheryavyy Y. A. Helicobacter pylori resistance in the Russian Federation: a meta-analysis of studies over the past 10 years. Therapeutic Archive. 2020; 92 (11): 24-30. (in Russ.) doi: 10.26442/00403660. 2020.11.000795.@@ Андреев Д. Н., Маев И. В., Кучерявый Ю. А. Резистентность Helicobacter pylori в Российской Федерации: метаанализ исследований за последние 10 лет. Терапевтический архив. 2020;92(11): 24-30.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Mayev I.V., Andreyev D. N., Bordin D. S. et al. Helicobacter pylori Resistance to Clarithromycin in the Russian Federation. Effective pharmacotherapy. 2020;16(30):16-22. (in Russ.) doi: 10.33978/2307-3586-2020-16-30-16-22.@@ Маев И. В., Андреев Д. Н., Бордин Д. С. и др. Резистентность Helicobacter pylori к кларитромицину в Российской Федерации. Эффективная фармакотерапия. 2020. Т. 16. № 30. С. 16-22. doi: 10.33978/2307-3586-2020-16-30-16-22.</mixed-citation><mixed-citation xml:lang="en">Mayev I.V., Andreyev D. N., Bordin D. S. et al. Helicobacter pylori Resistance to Clarithromycin in the Russian Federation. Effective pharmacotherapy. 2020;16(30):16-22. (in Russ.) doi: 10.33978/2307-3586-2020-16-30-16-22.@@ Маев И. В., Андреев Д. Н., Бордин Д. С. и др. Резистентность Helicobacter pylori к кларитромицину в Российской Федерации. Эффективная фармакотерапия. 2020. Т. 16. № 30. С. 16-22. doi: 10.33978/2307-3586-2020-16-30-16-22.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Grau S., Echeverria-Esnal D., Gómez-Zorrilla S. et al. Evolution of Antimicrobial Consumption During the First Wave of COVID-19 Pandemic. Antibiotics (Basel). 2021 Jan 29;10(2):132. doi: 10.3390/antibiotics10020132.</mixed-citation><mixed-citation xml:lang="en">Grau S., Echeverria-Esnal D., Gómez-Zorrilla S. et al. Evolution of Antimicrobial Consumption During the First Wave of COVID-19 Pandemic. Antibiotics (Basel). 2021 Jan 29;10(2):132. doi: 10.3390/antibiotics10020132.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Lucien M.A.B., Canarie M. F., Kilgore P. E. et al. Antibiotics and antimicrobial resistance in the COVID-19 era: Perspective from resource-limited settings.Int J Infect Dis. 2021 Mar;104:250-254. doi: 10.1016/j.ijid.2020.12.087.</mixed-citation><mixed-citation xml:lang="en">Lucien M.A.B., Canarie M. F., Kilgore P. E. et al. Antibiotics and antimicrobial resistance in the COVID-19 era: Perspective from resource-limited settings.Int J Infect Dis. 2021 Mar;104:250-254. doi: 10.1016/j.ijid.2020.12.087.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Zakharenkov I. A., Rachina S. A., Kozlov R. S., Belkova Yu. A. Consumption of systemic antibiotics in the Russian Federation in 2017-2021. Clinical Microbiology and Antimicrobial Chemotherapy. 2022; 24 (3): 220-225. (in Russ.) doi: 10.36488/cmac.2022.3.220-225.@@ Захаренков И. А., Рачина С. А., Козлов ВС., Белькова Ю. А. Потребление системных антибиотиков в России в 2017-2021 гг.: основные тенденции. Клиническая микробиология и антимикробная химиотерапия. 2022; 24 (3): 220-225. doi: 10.36488/cmac.2022.3.220-225.</mixed-citation><mixed-citation xml:lang="en">Zakharenkov I. A., Rachina S. A., Kozlov R. S., Belkova Yu. A. Consumption of systemic antibiotics in the Russian Federation in 2017-2021. Clinical Microbiology and Antimicrobial Chemotherapy. 2022; 24 (3): 220-225. (in Russ.) doi: 10.36488/cmac.2022.3.220-225.@@ Захаренков И. А., Рачина С. А., Козлов ВС., Белькова Ю. А. Потребление системных антибиотиков в России в 2017-2021 гг.: основные тенденции. Клиническая микробиология и антимикробная химиотерапия. 2022; 24 (3): 220-225. doi: 10.36488/cmac.2022.3.220-225.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Ivashkin V. T., Lapina T. L., Maev I. V. et al. Clinical Practice Guidelines of Russian Gastroenterological Association, Scientific Society for the Clinical Study of Human Microbiome, Russian Society for the Prevention of Non-Communicable Diseases, Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy for H. pylori Diagnostics and Treatment in Adults.Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022;32(6):72-93. (in Russ.) doi: 10.22416/1382-4376-2022-32-6-72-93.@@ Ивашкин В. Т., Лапина Т. Л., Маев И. В. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации, Научного сообщества по содействию клиническому изучению микробиома человека, Российского общества профилактики неинфекционных заболеваний, Межрегиональной ассоциации по клинической микробиологии и антимикробной химиотерапии по диагностике и лечению H. pylori у взрослых. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2022;32(6):72-93. doi: 10.22416/1382-4376-2022-32-6-72-93.</mixed-citation><mixed-citation xml:lang="en">Ivashkin V. T., Lapina T. L., Maev I. V. et al. Clinical Practice Guidelines of Russian Gastroenterological Association, Scientific Society for the Clinical Study of Human Microbiome, Russian Society for the Prevention of Non-Communicable Diseases, Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy for H. pylori Diagnostics and Treatment in Adults.Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022;32(6):72-93. (in Russ.) doi: 10.22416/1382-4376-2022-32-6-72-93.@@ Ивашкин В. Т., Лапина Т. Л., Маев И. В. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации, Научного сообщества по содействию клиническому изучению микробиома человека, Российского общества профилактики неинфекционных заболеваний, Межрегиональной ассоциации по клинической микробиологии и антимикробной химиотерапии по диагностике и лечению H. pylori у взрослых. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2022;32(6):72-93. doi: 10.22416/1382-4376-2022-32-6-72-93.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Kononov A.V., Mozgovoy S. I., Rybkina L. B., Bunova S. S., Shimanskaya A. G. Cytoprotective effect of bismuth tripotassium dicitrate on stomach mucosa at H. pylori eradication and prolonged drug administration. Ross z gastroenterol gepatol koloproktol. 2006; 16(6):21-8. (in Russ.)@@ Кононов А. В., Мозговой С. И., Рыбкина Л. Б., Бунова С. С., Шиманская А. Г. Оценка цитопротективного влияния висмута трикалия дицитрата на слизистую оболочку желудка при эрадикации H. pylori и пролонгированном приеме препарата. Рос журн гастроэнтерол гепатол колопроктол. 2006;16(6):21-8.</mixed-citation><mixed-citation xml:lang="en">Kononov A.V., Mozgovoy S. I., Rybkina L. B., Bunova S. S., Shimanskaya A. G. Cytoprotective effect of bismuth tripotassium dicitrate on stomach mucosa at H. pylori eradication and prolonged drug administration. Ross z gastroenterol gepatol koloproktol. 2006; 16(6):21-8. (in Russ.)@@ Кононов А. В., Мозговой С. И., Рыбкина Л. Б., Бунова С. С., Шиманская А. Г. Оценка цитопротективного влияния висмута трикалия дицитрата на слизистую оболочку желудка при эрадикации H. pylori и пролонгированном приеме препарата. Рос журн гастроэнтерол гепатол колопроктол. 2006;16(6):21-8.</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Arakawa T., Higuchi K., Fujiwara Y. et al. 15th anniversary of rebamipide: looking ahead to the new mechanisms and new applications. Dig Dis Sci. 2005;50 Suppl 1: S3-S11. doi: 10.1007/s10620-005-2800-9.</mixed-citation><mixed-citation xml:lang="en">Arakawa T., Higuchi K., Fujiwara Y. et al. 15th anniversary of rebamipide: looking ahead to the new mechanisms and new applications. Dig Dis Sci. 2005;50 Suppl 1: S3-S11. doi: 10.1007/s10620-005-2800-9.</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Andreev D. N., Maev I. V. Rebamipide: evidence base for use in gastroenterology. Terapevticheskii arkhiv. 2020;92(12):97-104. (in Russ.) doi: 10.26442/00403660. 2020.12.200455.@@ Андреев Д. Н., Маев И. В. Ребамипид: доказательная база применения в гастроэнтерологии. Терапевтический архив. 2020;92(12):97-104. doi: 10.26442/00403660.2020.12.200455.</mixed-citation><mixed-citation xml:lang="en">Andreev D. N., Maev I. V. Rebamipide: evidence base for use in gastroenterology. Terapevticheskii arkhiv. 2020;92(12):97-104. (in Russ.) doi: 10.26442/00403660. 2020.12.200455.@@ Андреев Д. Н., Маев И. В. Ребамипид: доказательная база применения в гастроэнтерологии. Терапевтический архив. 2020;92(12):97-104. doi: 10.26442/00403660.2020.12.200455.</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Li M., Yin T., Lin B. Rebamipide for chronic gastritis: a meta-analysis. Chinese J Gastroenterol Hepatol. 2015;24:667-73.</mixed-citation><mixed-citation xml:lang="en">Li M., Yin T., Lin B. Rebamipide for chronic gastritis: a meta-analysis. Chinese J Gastroenterol Hepatol. 2015;24:667-73.</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Haruma K., Ito M., Kido S. et al. Long-term rebamipide therapy improves Helicobacter pylori-associated chronic gastritis. Dig Dis Sci. 2002 Apr;47(4):862-7. doi: 10.1023/a:1014716822702.</mixed-citation><mixed-citation xml:lang="en">Haruma K., Ito M., Kido S. et al. Long-term rebamipide therapy improves Helicobacter pylori-associated chronic gastritis. Dig Dis Sci. 2002 Apr;47(4):862-7. doi: 10.1023/a:1014716822702.</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Kamada T., Sato M., Tokutomi T. et al. Rebamipide improves chronic inflammation in the lesser curvature of the corpus after Helicobacter pylori eradication: a multicenter study. Biomed Res Int. 2015;2015:865146. doi: 10.1155/2015/865146.</mixed-citation><mixed-citation xml:lang="en">Kamada T., Sato M., Tokutomi T. et al. Rebamipide improves chronic inflammation in the lesser curvature of the corpus after Helicobacter pylori eradication: a multicenter study. Biomed Res Int. 2015;2015:865146. doi: 10.1155/2015/865146.</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Lee J.S., Jeon S. W., Lee H. S., Kwon Y. H., Nam S. Y., Bae H. I., Seo A. N. Rebamipide for the Improvement of Gastric Atrophy and Intestinal Metaplasia: A Prospective, Randomized, Pilot Study. Dig Dis Sci. 2022 Jun;67(6):2395-2402. doi: 10.1007/s10620-021-07038-7.</mixed-citation><mixed-citation xml:lang="en">Lee J.S., Jeon S. W., Lee H. S., Kwon Y. H., Nam S. Y., Bae H. I., Seo A. N. Rebamipide for the Improvement of Gastric Atrophy and Intestinal Metaplasia: A Prospective, Randomized, Pilot Study. Dig Dis Sci. 2022 Jun;67(6):2395-2402. doi: 10.1007/s10620-021-07038-7.</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Ohashi H., Maruyama T., Higashi-Matsumoto H., Nomoto T., Nishimura S., Takeuchi Y. A novel binding assay for metabotropic glutamate receptors using [3H] L-quisqualic acid and recombinant receptors. Z Naturforsch C. 2002 57(3-4):348-355.</mixed-citation><mixed-citation xml:lang="en">Ohashi H., Maruyama T., Higashi-Matsumoto H., Nomoto T., Nishimura S., Takeuchi Y. A novel binding assay for metabotropic glutamate receptors using [3H] L-quisqualic acid and recombinant receptors. Z Naturforsch C. 2002 57(3-4):348-355.</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Shevtsov M., Smagina L., Kudriavtceva T., Petlenko S., Voronkina I. Glu-Trp-ONa or its acylated analogue (R-Glu-Trp-ONa) administration enhances the wound healing in the model of chronic skin wounds in rabbits. Drug Des Devel Ther. 2015 Mar 20;9:1717-27. doi: 10.2147/DDDT.S79665.</mixed-citation><mixed-citation xml:lang="en">Shevtsov M., Smagina L., Kudriavtceva T., Petlenko S., Voronkina I. Glu-Trp-ONa or its acylated analogue (R-Glu-Trp-ONa) administration enhances the wound healing in the model of chronic skin wounds in rabbits. Drug Des Devel Ther. 2015 Mar 20;9:1717-27. doi: 10.2147/DDDT.S79665.</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Golovacheva E.G., Starikova E. A., Kudryavtseva T. A., Apryatina V. A. The Effect of Drugs with α-Glutamyl-Tryptophan for Cytokine Secretion and Level of Surface Molecule ICAM-1 In Vitro. Cell tissue biol. 2023;17(2):146-152. doi: 10.1134/S1990519X23020050.</mixed-citation><mixed-citation xml:lang="en">Golovacheva E.G., Starikova E. A., Kudryavtseva T. A., Apryatina V. A. The Effect of Drugs with α-Glutamyl-Tryptophan for Cytokine Secretion and Level of Surface Molecule ICAM-1 In Vitro. Cell tissue biol. 2023;17(2):146-152. doi: 10.1134/S1990519X23020050.</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Uspenskiy Yu.P., Baryshnikova N. V., Krasnov A. A., Petlenko S. V., Apryatina V. A. The effectiveness of Regasthym Gastro in restoring acid production in the stomach according to daily pH-metry in patients with chronic atrophic gastritis. Experimental and Clinical Gastroenterology. 2022;(2):40-47. (In Russ.) doi: 10.31146/1682-8658-ecg-198-2-40-47.@@ Успенский Ю. П., Барышникова Н. В., Краснов А. А., Петленко С. В., Апрятина В. А. Влияние Регастим Гастро на восстановление кислотопродукции в желудке по данным суточной рН-метрии у больных хроническим атрофическим гастритом. Экспериментальная и клиническая гастроэнтерология. 2022;198(2): 40-47. doi: 10.31146/1682-8658-ecg-198-2-40-47.</mixed-citation><mixed-citation xml:lang="en">Uspenskiy Yu.P., Baryshnikova N. V., Krasnov A. A., Petlenko S. V., Apryatina V. A. The effectiveness of Regasthym Gastro in restoring acid production in the stomach according to daily pH-metry in patients with chronic atrophic gastritis. Experimental and Clinical Gastroenterology. 2022;(2):40-47. (In Russ.) doi: 10.31146/1682-8658-ecg-198-2-40-47.@@ Успенский Ю. П., Барышникова Н. В., Краснов А. А., Петленко С. В., Апрятина В. А. Влияние Регастим Гастро на восстановление кислотопродукции в желудке по данным суточной рН-метрии у больных хроническим атрофическим гастритом. Экспериментальная и клиническая гастроэнтерология. 2022;198(2): 40-47. doi: 10.31146/1682-8658-ecg-198-2-40-47.</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Baryshnikova N. V., Uspensky Yu.P., Kalinina E. Yu., Krasnov A. A., Petlenko S. V., Apryatina V. A. Alpha-glutamyl-tryptophan decreases inflammation in mucosa of patients with Helicobacter pylori associated atrophic gastritis.Russian Journal of Evidence-Based Gastroenterology. 2022;11(4):15-21. (In Russ.) doi: 10.17116/dokgastro20221104115.@@ Успенский Ю. П., Барышникова Н. В., Калинина Е. Ю., Краснов А. А., Петленко С. В., Апрятина В. А. Эффективность альфа-глутамил-триптофана в купировании воспаления у больных хроническим атрофическим гастритом, ассоциированным с Helicobacter pylori. Доказательная гастроэнтерология. 2022;11(4):1-7. doi: 10.17116/dokgastro20221104115.</mixed-citation><mixed-citation xml:lang="en">Baryshnikova N. V., Uspensky Yu.P., Kalinina E. Yu., Krasnov A. A., Petlenko S. V., Apryatina V. A. Alpha-glutamyl-tryptophan decreases inflammation in mucosa of patients with Helicobacter pylori associated atrophic gastritis.Russian Journal of Evidence-Based Gastroenterology. 2022;11(4):15-21. (In Russ.) doi: 10.17116/dokgastro20221104115.@@ Успенский Ю. П., Барышникова Н. В., Калинина Е. Ю., Краснов А. А., Петленко С. В., Апрятина В. А. Эффективность альфа-глутамил-триптофана в купировании воспаления у больных хроническим атрофическим гастритом, ассоциированным с Helicobacter pylori. Доказательная гастроэнтерология. 2022;11(4):1-7. doi: 10.17116/dokgastro20221104115.</mixed-citation></citation-alternatives></ref><ref id="cit61"><label>61</label><citation-alternatives><mixed-citation xml:lang="ru">Baryshnikova N. V., Uspenskiy Y. P., Fominykh Y. A., Petlenko S. V., Zaplutanov V. A., Apryatina V. A., Krasnov A. A. Endoscopic and morphometric analysis of the reduction of acute inflammatory process in the gastric mucosa after therapy with Regasthym Gastro. Terapevticheskii arkhiv. 2023;95(4):322-326. (in Russ.) doi: 10.26442/00403660.2023.04.202147.@@ Барышникова Н. В., Успенский Ю. П., Фоминых Ю. А., Петленко С. В., Заплутанов В. А., Апрятина В. А., Краснов А. А. Эндоскопический и морфометрический анализ редукции острого воспалительного процесса в слизистой оболочке желудка на фоне терапии препаратом Регастим Гастро. Терапевтический архив. 2023;95(4):322-326. doi: 10.26442/00403660.2023.04.202147.</mixed-citation><mixed-citation xml:lang="en">Baryshnikova N. V., Uspenskiy Y. P., Fominykh Y. A., Petlenko S. V., Zaplutanov V. A., Apryatina V. A., Krasnov A. A. Endoscopic and morphometric analysis of the reduction of acute inflammatory process in the gastric mucosa after therapy with Regasthym Gastro. Terapevticheskii arkhiv. 2023;95(4):322-326. (in Russ.) doi: 10.26442/00403660.2023.04.202147.@@ Барышникова Н. В., Успенский Ю. П., Фоминых Ю. А., Петленко С. В., Заплутанов В. А., Апрятина В. А., Краснов А. А. Эндоскопический и морфометрический анализ редукции острого воспалительного процесса в слизистой оболочке желудка на фоне терапии препаратом Регастим Гастро. Терапевтический архив. 2023;95(4):322-326. doi: 10.26442/00403660.2023.04.202147.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
